# Kalaris Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Kalaris Therapeutics, Inc.). ## Overview Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing TH103, its lead product candidate for neovascular age-related macular degeneration (nAMD). The company was formed through the March 2025 merger with AlloVir, after which the combined company adopted the Kalaris Therapeutics name and Legacy Kalaris became its operating business. ## Products & services • TH103 ophthalmology biologic candidate for nAMD • Preclinical development programs around TH103 • Phase 1a clinical trial of TH103 • Phase 1b/2 clinical trial of TH103 • Future product-candidate development and licensing - **Lead product candidate: TH103** (100%) — Clinical-stage biologic under development for nAMD and the company's main value driver. - **Preclinical pipeline development** (0%) — Earlier-stage research and development work intended to expand the product pipeline beyond TH103. - **Collaborations and licensing** (0%) — Strategic research, license, and sponsored-research arrangements that support development and IP access. - TH103 lead biologic candidate for neovascular age-related macular degeneration - Phase 1a clinical development of TH103 - Phase 1b/2 clinical development of TH103 - Preclinical research and translational development - In-licensing and collaboration-based pipeline expansion ## Customers Kalaris does not yet sell commercial products; its current 'customers' are primarily clinical investigators, trial sites, and strategic research partners that support development of TH103. If approved, the company expects to sell into the U.S. ophthalmology market, where retina specialists and the payors that reimburse treatment will determine adoption. - **Clinical trial investigators and sites** (primary) — They run Phase 1a and Phase 1b/2 studies and are essential for generating safety and efficacy data. - **Retina specialists / ophthalmologists** (primary) — Potential future prescribers of TH103 in nAMD if the product receives marketing approval. - **Payers and reimbursement gatekeepers** (primary) — They determine formulary access and pricing acceptance for a premium biologic versus biosimilars or generics. - **Research collaborators and licensors** (secondary) — Academic and industry partners that provide technology, IP, or sponsored research support. - Clinical trial sites enrolling nAMD patients for TH103 studies - Retina specialists who would prescribe TH103 if approved - Hospitals and ophthalmology centers participating in trials - Payers and insurers that influence access and pricing - Research collaborators and licensors supporting the pipeline ## Geography The company is headquartered in the United States and its current development work is centered on U.S. clinical and regulatory pathways, especially FDA approval for TH103. Management also references comparable foreign regulatory authorities, indicating that future development or approval efforts could extend beyond the U.S. if the program advances. - United States is the core operating and regulatory market - FDA pathway is the primary approval route for TH103 - Foreign regulators may matter if trials or approvals expand internationally - No commercial geography yet because the company has no product sales - Operations are concentrated in R&D, clinical, and corporate functions ## Strategy Kalaris is focused on advancing TH103 through clinical development, protecting its intellectual property, and preparing for eventual commercialization if the program succeeds. The company also needs to build manufacturing, regulatory, and sales capabilities, either internally or through partnerships, while managing a limited cash runway and the need for additional funding. - **Advance TH103 clinical development** (short-term) — Clinical data are the main value inflection point and the basis for future approval and commercialization. - **Prepare for regulatory approval and commercialization** (medium-term) — The company has no sales infrastructure and must be ready to launch if TH103 is approved. - **Strengthen IP and collaboration base** (medium-term) — Patent protection and external partnerships help defend the program and expand the pipeline. - Advance TH103 through Phase 1a and Phase 1b/2 trials - Generate data needed for FDA and other regulatory approvals - Protect and expand the patent portfolio around TH103 - Build commercialization capabilities for a future U.S. launch - Use collaborations and licensing to broaden the pipeline - Secure additional capital to fund development and operations ## Risks Kalaris faces the classic risks of a clinical-stage biotech: trial failure, regulatory delay, and the possibility that TH103 never reaches commercial approval. It also depends on single-source suppliers, external collaborators, and future financing, any of which could disrupt development or dilute shareholders. - **Clinical development failure for TH103** [critical] — The company depends on one lead candidate, so weak safety or efficacy data would materially impair value. - **Regulatory delay or denial** [high] — Approval depends on FDA and possibly foreign regulators, which may require additional studies or data. - **Single-source supplier dependence** [high] — A disruption in materials or components could delay trials and future manufacturing scale-up. - **Financing and dilution risk** [high] — The company expects continued losses and will need substantial additional funding. - **Commercialization execution risk** [medium] — Kalaris has no sales, marketing, or distribution infrastructure and may struggle to launch efficiently. - TH103 may fail in clinical trials or not show enough efficacy - FDA or foreign regulators may require more studies or delay approval - Single-source suppliers could disrupt clinical or future commercial supply - The company has no commercial sales infrastructure today - Additional financing will likely be needed before profitability ## Accounting The most important accounting judgments are tied to fair-value estimates, R&D accruals, and stock-based compensation, all of which can move materially as assumptions change. The merger also created one-time accounting effects, while the company’s clinical-stage model means losses and cash burn remain the key financial pattern rather than revenue recognition. - **Fair value of derivative liabilities and convertible notes** — Can materially affect reported net loss and period-to-period comparability - **Accrued research and development expenses** — Affects operating expenses and quarterly volatility - **Stock-based compensation** — Raises G&A and R&D expense without immediate cash outflow - **Merger-related accounting** — Can distort year-over-year comparisons around the closing date - Fair value estimates for derivative liabilities and convertible notes - R&D accruals depend on trial progress and vendor invoices - Stock-based compensation affects operating expense and equity - Merger accounting can create one-time valuation and remeasurement effects - No product revenue yet, so future revenue recognition is not currently a driver --- *Last updated: 2026-04-28T20:19:59.548872+00:00*